Q1 EPS Forecast for Axsome Therapeutics Increased by Analyst

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Equities researchers at Leerink Partnrs lifted their Q1 2025 EPS estimates for Axsome Therapeutics in a note issued to investors on Tuesday, February 18th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings per share of ($1.31) for the quarter, up from their previous forecast of ($1.48). The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.74) per share. Leerink Partnrs also issued estimates for Axsome Therapeutics’ Q2 2025 earnings at ($1.30) EPS, Q3 2025 earnings at ($1.12) EPS, Q4 2025 earnings at ($0.72) EPS, FY2025 earnings at ($4.45) EPS, FY2026 earnings at ($1.25) EPS and FY2027 earnings at $4.10 EPS.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.97) by $0.01. The business had revenue of $118.77 million for the quarter, compared to the consensus estimate of $117.83 million. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%.

Several other equities analysts also recently weighed in on AXSM. HC Wainwright raised their price target on shares of Axsome Therapeutics from $190.00 to $200.00 and gave the stock a “buy” rating in a research note on Thursday. Robert W. Baird set a $132.00 price target on shares of Axsome Therapeutics in a research note on Monday, February 3rd. Wells Fargo & Company raised their price target on shares of Axsome Therapeutics from $140.00 to $160.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 12th. StockNews.com raised shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Finally, Deutsche Bank Aktiengesellschaft began coverage on shares of Axsome Therapeutics in a research note on Tuesday, February 11th. They issued a “buy” rating and a $176.00 price target on the stock. One analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $158.79.

Axsome Therapeutics Stock Performance

AXSM opened at $137.75 on Friday. The company has a quick ratio of 2.37, a current ratio of 2.11 and a debt-to-equity ratio of 3.22. The company has a market cap of $6.72 billion, a price-to-earnings ratio of -23.00 and a beta of 1.05. Axsome Therapeutics has a 52-week low of $64.11 and a 52-week high of $139.13. The firm’s fifty day simple moving average is $101.29 and its two-hundred day simple moving average is $94.91.

Institutional Investors Weigh In On Axsome Therapeutics

Institutional investors have recently made changes to their positions in the stock. Raiffeisen Bank International AG acquired a new stake in shares of Axsome Therapeutics during the fourth quarter valued at about $51,000. Assetmark Inc. acquired a new stake in shares of Axsome Therapeutics during the fourth quarter valued at about $52,000. R Squared Ltd acquired a new stake in shares of Axsome Therapeutics during the fourth quarter valued at about $64,000. Aquatic Capital Management LLC acquired a new stake in shares of Axsome Therapeutics during the fourth quarter valued at about $76,000. Finally, GF Fund Management CO. LTD. acquired a new stake in shares of Axsome Therapeutics during the fourth quarter valued at about $86,000. 81.49% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of Axsome Therapeutics stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $131.07, for a total transaction of $393,210.00. Following the completion of the sale, the chief financial officer now directly owns 42,187 shares in the company, valued at $5,529,450.09. This trade represents a 6.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 22.40% of the stock is owned by company insiders.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.